These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24582759)

  • 81. Therapeutic drug monitoring of natalizumab.
    Tanaka M
    Mult Scler; 2019 Oct; 25(12):1689-1690. PubMed ID: 30485149
    [No Abstract]   [Full Text] [Related]  

  • 82. Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.
    Meira M; Sievers C; Hoffmann F; Rasenack M; Kuhle J; Derfuss T; Kappos L; Lindberg RL
    J Immunol Res; 2014; 2014():897249. PubMed ID: 24901013
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Melatonin reduces inflammatory response in peripheral T helper lymphocytes from relapsing-remitting multiple sclerosis patients.
    Álvarez-Sánchez N; Cruz-Chamorro I; Díaz-Sánchez M; Sarmiento-Soto H; Medrano-Campillo P; Martínez-López A; Lardone PJ; Guerrero JM; Carrillo-Vico A
    J Pineal Res; 2017 Nov; 63(4):. PubMed ID: 28793364
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Transient gadolinium leakage in natalizumab-treated multiple sclerosis.
    Haller S; Barkhof F; Wattjes MP; Lalive PH
    J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):475-6. PubMed ID: 25246642
    [No Abstract]   [Full Text] [Related]  

  • 85. Evidence for possible role of melatonin in reducing oxidative stress in multiple sclerosis through its effect on SIRT1 and antioxidant enzymes.
    Emamgholipour S; Hossein-Nezhad A; Sahraian MA; Askarisadr F; Ansari M
    Life Sci; 2016 Jan; 145():34-41. PubMed ID: 26679105
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Natalizumab treatment for multiple sclerosis inducing a toxic acute myocardial damage. Is there any relationship?
    Fama' F; Dattola V; Cicciu' M; Buccafusca M; Russo M; Lo Presti D; Dattilo G; Di Bella G
    Int J Cardiol; 2016 Mar; 206():127-8. PubMed ID: 26788687
    [No Abstract]   [Full Text] [Related]  

  • 87. Improvement of visual acuity in patients with severe visual loss affected by multiple sclerosis treated with natalizumab: a case report.
    Florio C; Maniscalco GT
    Neurol Sci; 2011 Jan; 31 Suppl 3():325-7. PubMed ID: 20596742
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Kropshofer H; Häring DA; Kappos L; Leppert D; Kuhle J
    Neurology; 2022 Mar; 98(11):470-471. PubMed ID: 35288475
    [No Abstract]   [Full Text] [Related]  

  • 89. Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Bridel C; Killestein J; Teunissen C
    Neurology; 2022 Mar; 98(11):471. PubMed ID: 35288476
    [No Abstract]   [Full Text] [Related]  

  • 90. Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis.
    Henderson CE
    Acta Neurol Scand; 2012 Jul; 126(1):e7. PubMed ID: 22671933
    [No Abstract]   [Full Text] [Related]  

  • 91. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis.
    Ortiz GG; Macías-Islas MA; Pacheco-Moisés FP; Cruz-Ramos JA; Sustersik S; Barba EA; Aguayo A
    Dis Markers; 2009; 26(1):35-9. PubMed ID: 19242067
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [New approaches to antioxidant therapy in multiple sclerosis].
    Odinak MM; Bisaga GN; Zarubina IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; Suppl():72-5. PubMed ID: 12418396
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis: effect of corticosteroid therapy.
    Seven A; Aslan M; Incir S; Altıntaş A
    Folia Neuropathol; 2013; 51(1):58-64. PubMed ID: 23553138
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Natalizumab in multiple sclerosis: the second treatment revolution].
    Tourbah A
    Presse Med; 2008 Jan; 37(1 Pt 2):81-4. PubMed ID: 18031976
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Evaluation of serum arsenic and its effects on antioxidant alterations in relapsing-remitting multiple sclerosis patients.
    Juybari KB; Ebrahimi G; Momeni Moghaddam MA; Asadikaram G; Torkzadeh-Mahani M; Akbari M; Mirzamohammadi S; Karimi A; Nematollahi MH
    Mult Scler Relat Disord; 2018 Jan; 19():79-84. PubMed ID: 29156301
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Switching from natalizumab to ocrelizumab in patients with multiple sclerosis.
    Levin SN; Ezuma C; Levine L; Vargas WS; Farber RS; De Jager PL; Riley CS
    Mult Scler; 2020 Dec; 26(14):1964-1965. PubMed ID: 32552363
    [No Abstract]   [Full Text] [Related]  

  • 97. Rational therapy for relapsing multiple sclerosis.
    Wolinsky JS
    Lancet Neurol; 2003 May; 2(5):271-2. PubMed ID: 12849176
    [No Abstract]   [Full Text] [Related]  

  • 98. Breathlessness, night sweats, and weight loss on natalizumab.
    Dahdaleh D; Altmann DM; Malik O; Nicholas RS
    Lancet; 2012 Aug; 380(9843):726-7. PubMed ID: 22920745
    [No Abstract]   [Full Text] [Related]  

  • 99. Age-dependent effects on the treatment response of natalizumab in MS patients.
    Matell H; Lycke J; Svenningsson A; Holmén C; Khademi M; Hillert J; Olsson T; Piehl F
    Mult Scler; 2015 Jan; 21(1):48-56. PubMed ID: 24866201
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Severe anemia in a patient with multiple sclerosis treated with natalizumab.
    Seibert JB; Alvarez E
    Neurology; 2015 Feb; 84(8):861. PubMed ID: 25713115
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.